Replimune, Inc.

REPL · Nasdaq · United States

Share price · REPL

$19.81+4.23 (+27.15%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.1M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when REPL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026+10.7%
  2. 28 Oct 2026+23.1%
  3. 31 Jul 2026+107.0%
  4. 28 Jul 2026-38.0%
  5. 29 May 2026+85.7%
  6. 13 May 2026+29.6%
  7. 23 Apr 2026+25.6%
  8. 13 Apr 2026-64.3%
  9. 10 Apr 2026-19.5%

    Nothing announced by REPL that day or the session before.

  10. 8 Apr 2026-24.6%

Share of unusual movement by asset

For each asset, the share of REPL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Vusolimogene oderparepvec (Tudriqev) (Tudriqev)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—62%
Sessions with no dated event—37%

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
No discrete molecular targetOncolytic virus
Non-Small Cell Lung CancerMelanoma
Phase 2/3
Oncolytic HSV-1 (tumour lysis and immune stimulation)Oncolytic virus
Uveal Melanoma

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Sturlimogene erparepvecPhase 2Hepatocellular Carcinoma, Biliary Tract Cancer
Est. primary completion 2027-12-01 · NCT05733598 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Vusolimogene oderparepvec (Tudriqev)Phase 2Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
Est. primary completion 2028-06 · NCT03767348 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Vusolimogene oderparepvec (Tudriqev)Phase 1/2Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
Est. primary completion 2029-07 · NCT04349436 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Sturlimogene erparepvecPhase 2/3Metastatic Uveal Melanoma
Est. primary completion 2030-01 · NCT06581406 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 August 2026ApprovalVusolimogene oderparepvec (Tudriqev)FDA grants accelerated approval to Tudriqev with nivolumab in advanced melanoma
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$34M$310M+ $0 short-term inv.$57M-$48M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$49M$187M+ $10.0M short-term inv.$70M-$76M operating cash flowreport ↗
2025-Q4—$53M$125M+ $146M short-term inv.$71M-$66M operating cash flowreport ↗
2025-Q3—$58M$104M+ $221M short-term inv.$83M-$81M operating cash flowreport ↗
2025-Q2—$58M$99M+ $306M short-term inv.$87M-$77M operating cash flowreport ↗
2024-Q4—$48M$174M+ $364M short-term inv.$66M-$51M operating cash flowreport ↗
2024-Q3—$43M$115M+ $319M short-term inv.$53M-$39M operating cash flowreport ↗
2024-Q2—$43M$153M+ $317M short-term inv.$54M-$49M operating cash flowreport ↗
2023-Q4—$43M$99M+ $369M short-term inv.$51M-$47M operating cash flowreport ↗
2023-Q3—$49M$78M+ $421M short-term inv.$60M-$44M operating cash flowreport ↗
2023-Q2—$40M$108M+ $433M short-term inv.$50M-$49M operating cash flowreport ↗
2022-Q4—$30M$208M+ $410M short-term inv.$40M-$29M operating cash flowreport ↗
2022-Q3—$29M$91M+ $283M short-term inv.$43M-$33M operating cash flowreport ↗
2022-Q2—$29M$114M+ $283M short-term inv.$42M-$33M operating cash flowreport ↗
2021-Q4—$19M$134M+ $288M short-term inv.$30M-$18M operating cash flowreport ↗
2021-Q3—$20M$162M+ $276M short-term inv.$29M-$23M operating cash flowreport ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY—$221M$211M+ $60M short-term inv.$78M-$280M operating cash flowreport ↗

Replimune did not disclose revenue for fiscal year 2026, and prior-year revenue was also not disclosed. R&D expense was $221.18M, up 16.7% YoY from $189.45M. Cash and equivalents were $210.73M, while cash, cash equivalents and short-term investments totaled $268.9M as of March 31, 2026. The company reported a net loss of $313.94M for the fiscal year.

The FDA accepted for review the resubmitted BLA for RP1 in combination with nivolumab for advanced melanoma, with a goal date of August 2, 2026 and an advisory committee meeting expected in late July. The company highlighted durable survival data from the IGNYTE trial, active enrollment in the IGNYTE-3 and REVEAL trials, and a planned Phase 2/3 transition in Q1 2027. Based on its current operating plan, existing cash, cash equivalents and short-term investments are expected to fund operations into the first quarter of calendar 2027, excluding any potential revenue.

View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$189M$113M+ $373M short-term inv.$62M-$192M operating cash flowreport ↗
2024-FY—$175M$76M+ $346M short-term inv.$54M-$185M operating cash flowreport ↗
2023-FY—$127M$148M+ $437M short-term inv.$44M-$128M operating cash flowreport ↗
2022-FY—$80M$108M+ $290M short-term inv.$30M-$82M operating cash flowreport ↗
2021-FY—$57M$184M+ $294M short-term inv.$20M-$61M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 21 sales ($4.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Hill Emily Luisa · Chief Financial OfficerOpen-market sale14,709$21.60$318KForm 4
2026-11-16Patel Sushil · director, Chief Executive OfficerOpen-market sale49,026$21.60$1.1MForm 4
2026-11-16Schwendenman Andrew · Chief Accounting OfficerOpen-market sale2,148$21.60$46KForm 4
2026-11-16Xynos Konstantinos · Chief Medical OfficerOpen-market sale16,198$21.60$350KForm 4
2026-11-09SLATTERY JOSEPH P · directorOpen-market sale5,200$21.80$113KForm 4
2026-11-02Dhingra Kapil · directorOption exercise43,169$1.75$76KForm 4
2026-11-02Dhingra Kapil · directorOpen-market sale21,500$19.00$409KForm 4
2026-11-02Dhingra Kapil · directorOption exercise (derivative)43,169——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 179 reporting institutions held 81.1M shares ($552.6M, 86.1% of shares outstanding).

#InstitutionSharesValue
1BAKER BROS. ADVISORS LP11,045,336$84.5M
2RTW INVESTMENTS, LP7,356,916$56.3M
3BlackRock, Inc.6,239,239$47.7M
4SUVRETTA CAPITAL MANAGEMENT, LLC4,221,836$32.3M
5STATE STREET CORP3,782,237$28.9M
6FCPM III SERVICES B.V.2,808,368$21.5M
7VANGUARD CAPITAL MANAGEMENT LLC2,759,120$21.1M
8D. E. Shaw & Co., Inc.2,336,528$17.9M
9GOLDMAN SACHS GROUP INC2,277,276$17.4M
10FMR LLC2,045,490$15.6M
11Erste Asset Management GmbH2,120,000$15.3M
12GEODE CAPITAL MANAGEMENT, LLC1,801,525$13.8M
13TORONTO DOMINION BANK1,591,030$12.2M
14ADAR1 Capital Management, LLC1,582,987$12.1M
15Boxer Capital Management, LLC1,175,000$9.0M